Federal Pharmaceuticals (03933): Amoxicillin granules passed the consistent evaluation of generic drug quality and efficacy

Zhitongcaijing · 10/16 14:49

Zhitong Financial App News, Federal Pharmaceutical (03933) announced that amoxicillin granules (specification: 0.125g) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, have been approved by the China National Drug Administration and passed the consistent evaluation of the quality and efficacy of generic drugs.

Amoxicillin granules are a penicillin-type broad-spectrum antibiotic clinically suitable for respiratory infections, urogenital infections, skin soft tissue infections, and combination with other drugs to eradicate Helicobacter pylori in adults and children caused by sensitive bacteria (not producing beta-lactamase strains). It is widely used clinically, has remarkable curative effects, and is well adhered to by patients. Currently, amoxicillin granules are Class A drugs in the National Basic Drug Catalogue (2018 edition) and the National Medical Insurance Catalogue (2023 edition).

This approval will further help the company consolidate its dominant position in the anti-infective field. The company will continue to work on developing new products and promoting consistency evaluations, which is expected to generate greater benefits for the company and its shareholders.